One of the health highlights mentioned in this update compiled by editors outlines the conclusions from a recent ISMP QuarterWatch report that examined many unanswered questions about the safety and effectiveness of pimavanserin (Nuplazid), a drug used to treat psychosis in Parkinson's patients, and called for stronger warnings on its label.
For the full text, visit U.S. News & World Report online.
More News
This article appeared on the Drug Topics website on January 18, 2021.
This article appeared on the American Nurse website on January 15, 2021.
This article appeared on the Becker’s Hospital Review website on January 15, 2021.